Review Article
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Table 1
Molecular biomarkers in GBM.
| p53 signalling altered in 87% | MDM2 (amplification in 14%) | RTK/RAS/PI3 signalling altered in 88% | PI3K (mutation in 15%) | RB signaling altered in 78% | CDK4 (amplification in 18%) |
|
|